浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Effect and mechanism of asperuloside on liver fibrosis in non-alcoholic fatty liver rats
- ZHONGGUO YAOFANG Vol. 35, Issue 17, Pages: 2102-2107(2024)
- 作者机构：
武汉市中医医院脾胃肝胆病科，武汉 430010
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2024.17.08
CLC： R965;R285.5Published：15 September 2024，
Received：18 March 2024，
Revised：01 August 2024，
- 稿件说明：
移动端阅览
梁金,许丹,杜进军.车叶草苷对非酒精性脂肪性肝病大鼠肝纤维化的影响及机制 Δ[J].中国药房,2024,35(17):2102-2107.
LIANG Jin,XU Dan,DU Jinjun.Effect and mechanism of asperuloside on liver fibrosis in non-alcoholic fatty liver rats[J].ZHONGGUO YAOFANG,2024,35(17):2102-2107.
梁金,许丹,杜进军.车叶草苷对非酒精性脂肪性肝病大鼠肝纤维化的影响及机制 Δ[J].中国药房,2024,35(17):2102-2107. DOI： 10.6039/j.issn.1001-0408.2024.17.08.
LIANG Jin,XU Dan,DU Jinjun.Effect and mechanism of asperuloside on liver fibrosis in non-alcoholic fatty liver rats[J].ZHONGGUO YAOFANG,2024,35(17):2102-2107. DOI： 10.6039/j.issn.1001-0408.2024.17.08.
摘要
目的
2
探究车叶草苷调节鞘氨醇激酶1（SphK1）/1-磷酸鞘氨醇（S1P）信号通路对非酒精性脂肪性肝病（NAFLD）大鼠肝纤维化的影响及机制。
方法
2
以高脂饲料饲养的方法建立大鼠NAFLD模型，将造模成功的大鼠随机分为模型组、车叶草苷低剂量组（14 mg/kg，灌胃，下同）、车叶草苷高剂量组（28 mg/kg）、车叶草苷高剂量（28 mg/kg）+pc-NC（空载质粒，50 µg，尾静脉注射，下同）组、车叶草苷高剂量（28 mg/kg）+pc-SphK1（SphK1过表达质粒，50 µg）组，每组12只。另取12只大鼠以正常饲料饲养作为对照组。各组大鼠灌胃或尾静脉注射相应药物或质粒，灌胃处理每天1次，尾静脉注射处理每周2次，均连续3周。末次给药后，检测各组大鼠血脂指标[总胆固醇（TC）、甘油三酯（TG）、游离脂肪酸（FFA）
]
与肝功能指标[天冬氨酸转氨酶（AST）和丙氨酸转氨酶（ALT）
]
水平；观察大鼠肝组织病理变化以及肝纤维化情况；检测大鼠血清纤维化相关因子[Ⅲ型前胶原（PCⅢ）、Ⅳ型胶原（Ⅳ-Col）、层粘连蛋白（LN）
]
、促纤维化因子[转化生长因子β
1
（TGF-β
1
）
]
与促炎因子[白细胞介素1β（IL-1β）、诱导型一氧化氮合酶（iNOS）、IL-6
]
水平；检测大鼠肝组织胶原形成相关蛋白（Ⅰ-Col、Ⅳ-Col）与SphK1/S1P信号通路相关蛋白表达。
结果
2
与对照组比较，模型组大鼠肝组织呈现明显病理损伤症状；NAFLD活动度评分、肝组织胶原容积分数（CVF）和血清中TC、TG、FFA、AST、ALT、PCⅢ、Ⅳ-Col、LN、TGF-β
1
、IL-1β、iNOS、IL-6水平以及肝组织中Ⅰ-Col、Ⅳ-Col、SphK1、S1P蛋白表达水平均显著升高（
P
＜0.05）。与模型组比较，车叶草苷低、高剂量组大鼠肝组织病理损伤症状均减轻，上述指标水平均显著降低（
P
＜0.05），且高剂量组降低效果更好（
P
＜0.05）。与车叶草苷高剂量组和车叶草苷高剂量+pc-NC组比较，车叶草苷高剂量+pc-SphK1组大鼠肝组织病理损伤症状加重，上述指标水平均显著升高（
P
＜0.05）。
结论
2
车叶草苷可通过抑制SphK1/S1P信号通路活性，降低促纤维化因子、促炎因子以及胶原形成蛋白表达，从而减轻NAFLD大鼠肝纤维化。
Abstract
OBJECTIVE
2
To investigate the effect and mechanism of asperuloside on liver fibrosis in non-alcoholic fatty liver disease （NAFLD） rats by regulating the sphingosine kinase 1 （SphK1）/sphingosine-1-phosphate （S1P） signaling pathway.
METHODS
2
SD rats were fed with a high-fat diet to establish a NAFLD model. They were randomly separated into model group， asper
uloside low-dose group （14 mg/kg， i.g.， similarly hereinafter）， asperuloside high-dose group （28 mg/kg）， high dose of asperuloside （28 mg/kg）+pc-NC （empty plasmid， 50 µg， via tail vein， similarly hereinafter） group， and high dose of asperuloside （28 mg/kg）+pc-SphK1 （SphK1 overexpression plasmid， 50 µg） group， with 12 rats in each group. Another 12 rats were fed with a normal diet as control group. Each group was given relevant medicine or plasmid intragastrically once a day or via tail vein twice a week， for 3 consecutive weeks. After the last medication， the levels of blood lipid indexes [total cholesterol （TC）， triglyceride （TG）， and free fatty acid （FFA）
]
and liver function indexes [aspartate transaminase （AST） and alanine transaminase （ALT）
]
were detected in each group. The pathological changes of liver tissue and liver fibrosis in rats were also observed in each group. The levels of serum fibrosis-related factors [procollagen type Ⅲ （PCⅢ）， collagen type Ⅳ （Ⅳ-Col）， laminin （LN）
]
， pro-fibrotic factor [transforming growth factor-β
1
（TGF-β
1
）
]
， and pro-inflammatory factors [interleukin-1β （IL-1β）， inducible nitric oxide synthase （iNOS）， IL-6
]
of rats were determined in each group. The expressions of collagen formation-related proteins （Ⅰ-Col， Ⅳ-Col） and SphK1/S1P pathway-related proteins in the liver tissues of rats were detected in each group.
RESULTS
2
Compared with control group， the liver tissue of rats in model group showed significant pathological damage； the NAFLD activity score， liver tissue collagen volume fraction， serum levels of TC， TG， FFA， AST， ALT， PCⅢ， Ⅳ-Col， LN， TGF-β
1
， IL-1β， iNOS and IL-6， and protein expressions of Ⅰ-Col， Ⅳ-Col， SphK1 and S1P in liver tissue were greatly increased （
P
＜0.05）. Compared with the model group， the liver tissue pathological damage symptoms of rats in asperuloside low-dose and high-dose groups were improved， and the above indexes were all reduced significantly （
P
＜0.05）； mor
eover， the high-dose group had a better effect （
P
＜0.05）. Compared to asperuloside high-dose group， high dose of asperuloside+pc-NC group， the pathological damage of liver tissue symptoms in rats were aggravated in high dose of asperuloside+pc-SphK1 group， and the above indexes were all increased significantly （
P
＜0.05）.
CONCLUSIONS
2
Asperuloside can reduce the expressions of pro-fibrotic factor， pro-inflammatory factors and collagen formation-related proteins by inhibiting the activity of SphK1/S1P signaling pathway， thus alleviating liver fibrosis in NAFLD rats.
关键词
车叶草苷非酒精性脂肪性肝病肝纤维化SphK1/S1P信号通路
Keywords
non-alcoholic fatty liver diseaseliver fibrosisSphK1/S1P signaling pathway
references
TINCOPA M A，LOOMBA R. Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J]. Lancet Gastroenterol Hepatol，2023，8（7）：660-670.
HAN S K，BAIK S K，KIM M Y. Non-alcoholic fatty liver disease：definition and subtypes[J]. Clin Mol Hepatol，2023，29（Suppl.）：S5-S16.
RINELLA M E，NEUSCHWANDER-TETRI B A，SIDDIQUI M S，et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology，2023，77（5）：1797-1835.
HAMMERICH L，TACKE F. Hepatic inflammatory responses in liver fibrosis[J]. Nat Rev Gastroenterol Hepatol，2023，20（10）：633-646.
TAKESHITA Y，HONDA M，HARADA K，et al. Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes：a randomized，48-week，open-label，active-controlled trial[J]. Diabetes Care，2022，45（9）：2064-2075.
FENG F Z，GONG W Y，LI S Y，et al. Inhibitory effect of resveratrol on LPS-induced glomerular mesangial cells proliferation and TGF-β1 expression via sphingosine kinase 1 pathway[J]. Chin J Integr Med，2023，29（6）：500-507.
ZHOU Z S，KONG C F，SUN J R，et al. Fisetin ameliorates alcohol-induced liver injury through regulating SIRT1 and SphK1 pathway[J]. 2022，50（8）：2171-2184.
ABDELRAHEEM K M，YOUNIS N N，SHAHEEN M A，et al. Raspberry ketone improves non-alcoholic fatty liver disease induced in rats by modulating sphingosine kinase/sphingosine-1-phosphate and toll-like receptor 4 pathways[J]. J Pharm Pharmacol，2023，75（7）：985-994.
UCZAY M，PFLÜGER P，PICADA J N，et al. Geniposide and asperuloside alter the COX-2 and GluN2B receptor expression after pilocarpine-induced seizures in mice[J]. Naunyn Schmiedebergs Arch Pharmacol，2023，396（5）：951-962.
CHEN Q，ZHANG Q J，AMROUCHE A T，et al. Asperuloside，the bioactive compound in the edible Eucommia ulmoides male flower，delays muscle aging by daf-16 media- ted improvement in mitochondrial dysfunction[J]. Food Funct，2023，14（12）：5562-5575.
SHEN Q，CHEN Y E，SHI J X，et al. Asperuloside allevia- tes lipid accumulation and inflammation in HFD-induced NAFLD via AMPK signaling pathway and NLRP3 inflammasome[J]. Eur J Pharmacol，2023，942：175504.
李芳，陈华伟，钟军华，等. 槲皮苷对非酒精性脂肪肝大鼠肝纤维化和炎症作用研究[J]. 中国临床药理学杂志，2023，39（12）：1753-1757.
LI F，CHEN H W，ZHONG J H，et al. Effect of quercitrin on liver fibrosis and inflammation in non-alcoholic fatty liver rats[J]. Chin J Clin Pharmacol，2023，39（12）：1753-1757.
丁静，张斌，魏冬梅，等. 盐酸小檗碱对非酒精性脂肪肝大鼠肝脏氧化应激水平及Nrf2表达的影响[J]. 免疫学杂志，2020，36（3）：201-207.
DING J，ZHANG B，WEI D M，et al. Effects of berberine hydrochloride on liver oxidative stress and nuclear Nrf2 expression in rats with nonalcoholic fatty liver disease[J]. Immunol J，2020，36（3）：201-207.
LEE K C，WU P S，LIN H C. Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis[J]. Clin Mol Hepatol，2023，29（1）：77-98.
FAN X D，ZHOU C，HUANG C，et al. Asperuloside ameliorates lipopolysaccharide-induced primary human perio- dontal ligament cell injury by decreasing TLR4 expression and NF-κB activation[J]. Arch Oral Biol，2021，129：105199.
KONG Z Y，LIU C H，OLATUNJI O J. Asperuloside attenuates cadmium-induced toxicity by inhibiting oxidative stress，inflammation，fibrosis and apoptosis in rats[J]. Sci Rep，2023，13（1）：5698.
JOZEFCZUK E，SZCZEPANIAK P，GUZIK T J，et al. Silencing of Sphingosine kinase 1 affects maturation pathways in mouse neonatal cardiomyocytes[J]. Int J Mol Sci，2021，22（7）：3616.
MONTEFUSCO D，JAMIL M，MACZIS M A，et al. Sphingosine kinase 1 mediates sexual dimorphism in fibrosis in a mouse model of NASH[J]. Mol Metab，2022，62：101523.
0
Views
0
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.